Such an activated T cell might encounter an AML blast presenting the same peptide ... cell epitope peptide derived from a LAA. AML: Acute myeloid leukemia; CTL: Cytotoxic T lymphocyte; FasL ...

AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiatedBLA approval triggers $30m milestone payment to Autolus ...

That was among the many special moments for 11-year-old Cooper Trueblood at the Washington Capitals’ annual Hockey Fights ...

The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Researchers have identified a key weakness in acute ... leukemia, offering a promising new strategy to delay the progression ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...